GlassScriptPhysician profile
Joshua Waltzman
NPI 1194967240
$5,976.83
in general payments reported to CMS, 2019-2025
13 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,110 · 2020: $472 · 2021: $1,303 · 2022: $839 · 2023: $38.65 · 2024: $807 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sientra, INC. | $2,216.14 | 2019-2022 | |
| Apyx Medical Corporation | $1,361.53 | 2019 | |
| Allergan, INC. | $637.36 | 2019-2022 | |
| Motiva USA, LLC | $632.99 | 2024-2025 | |
| Abbvie INC. | $269.99 | 2024 | |
| Polynovo North America LLC | $167.93 | 2024 | Novosorb Btm |
| Bard Peripheral Vascular, INC. | $145.28 | 2021 | |
| Galderma Laboratories, L.P. | $129.31 | 2019-2025 | |
| Tela Bio, INC. | $125.48 | 2021-2024 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Davol INC. | $105.43 | 2022 | |
| Mentor Worldwide LLC | $104.05 | 2019-2022 | |
| Revance Therapeutics, INC. | $47.75 | 2024 | Daxxify |
| Pacira Pharmaceuticals Incorporated | $33.59 | 2021-2023 | Iovera, Exparel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Waltzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.